Eculizumab therapy

Biol Blood Marrow Transplant. 2014 Apr;20(4):438-9. doi: 10.1016/j.bbmt.2014.02.006. Epub 2014 Feb 15.

Author

Spero R Cataland¹

Affiliation

¹ Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio. Electronic address: spero.cataland@osumc.edu.

PMID: 24534107
DOI: 10.1016/j.bbmt.2014.02.006

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Atypical Hemolytic Uremic Syndrome
Child
Complement Inactivating Agents / therapeutic use*
Complement Membrane Attack Complex / antagonists & inhibitors*
Hematopoietic Stem Cell Transplantation / adverse effects
Hemoglobinuria, Paroxysmal / drug therapy
Hemoglobinuria, Paroxysmal / immunology
Hemoglobinuria, Paroxysmal / pathology
Hemolytic-Uremic Syndrome / drug therapy
Hemolytic-Uremic Syndrome / immunology
Hemolytic-Uremic Syndrome / pathology
Humans
Thrombotic Microangiopathies / drug therapy*
Thrombotic Microangiopathies / etiology
Thrombotic Microangiopathies / immunology
Thrombotic Microangiopathies / pathology

Substances

Antibodies, Monoclonal, Humanized
Complement Inactivating Agents
Complement Membrane Attack Complex
eculizumab